Publications by authors named "Caterina Macrini"
Article Synopsis
- The study investigated whether Biozzi mice with experimental autoimmune encephalomyelitis (EAE) mimic the disease progression and immune responses seen in progressive multiple sclerosis (MS).
- Findings showed that chronic EAE in these mice displayed characteristics such as relapsing disease stages, altered blood-brain barrier (BBB) function, and the formation of ectopic lymphoid tissues that relate to tissue damage.
- The immune response shifted from being T cell-dominant during relapses to B cell-dominant in later stages, suggesting that late chronic EAE may serve as an effective model for researching treatments for progressive MS.
Article Synopsis
- * The research showed that the N-terminal part of MOG alone is insufficient for ELISA-based identification of MOG antibodies in patients, indicating that full-length MOG is required for effective antibody binding.
- * The intracellular part of MOG is crucial in maintaining optimal spacing for bivalent binding of antibodies, highlighting the necessity of a cell-based approach for identifying MOG-Abs in patients.
Article Synopsis
- Autoimmune disorders of the central nervous system (CNS) are diverse, and understanding the specific autoantigens is crucial for improving therapy and understanding disease causes.
- Researchers studied oligodendrocyte myelin glycoprotein (OMGP) as a potential autoimmune target and found autoantibodies to OMGP in a small percentage of multiple sclerosis patients, a child with encephalomyelitis, and one patient with psychosis, but not in healthy controls.
- The presence of OMGP-specific T cells in an animal model led to a new type of experimental autoimmune encephalomyelitis characterized by unusual inflammation, emphasizing the role of OMGP in patient diagnostic and therapeutic stratification.
Identification of circulating MOG-specific B cells in patients with MOG antibodies.
Neurol Neuroimmunol Neuroinflamm
November 2019
Article Synopsis
- The study aimed to identify circulating MOG-specific B cells in the blood of patients with MOG antibodies and investigate their relationship with serum anti-MOG antibody levels and epitope specificity.
- Researchers analyzed blood samples from 21 MOG-antibody-positive patients and 26 controls, finding that a higher frequency of MOG-specific B cells was present in patients, but only about 60% of them tested positive for these B cells.
- The findings suggest that the quantity of circulating MOG-specific B cells varies significantly among patients and does not correlate with serum MOG antibody levels, indicating potential differences in the sources of these antibodies, which could inform future patient-specific treatments.
Autoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of patients with inflammatory demyelination and are detected with MOG-transfected cells. While the prototype anti-MOG mAb 8-18C5 and polyclonal anti-MOG responses from different mouse strains largely recognize the FG loop of MOG, the human anti-MOG response is more heterogeneous and human MOG-Abs recognizing different epitopes were found to be pathogenic. The aim of this study was to get further insight into details of antigen-recognition by human MOG-Abs focusing on the impact of glycosylation.
View Article and Find Full Text PDFArticle Synopsis
- Autoreactive CD4 T-cells play a significant role in driving multiple sclerosis (MS), with myelin oligodendrocyte glycoprotein (MOG) being a key autoantigen, although its significance has been questioned due to low detection rates.
- This study utilized a novel method with bead-bound MOG to analyze T-cell reactivity and found that a higher frequency of MOG-specific T-cells producing cytokines (IFNγ, IL-22, IL-17A) was present in individuals with MS compared to healthy controls.
- Approximately 46.2-59.6% of MS patients exhibited MOG-reactivity, and blocking specific immune cells eliminated this response, indicating that MOG
Objective: Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) occur in a proportion of patients with inflammatory demyelinating diseases of the central nervous system (CNS). We analyzed their pathogenic activity by affinity-purifying these antibodies (Abs) from patients and transferring them to experimental animals.
Methods: Patients with Abs to MOG were identified by cell-based assay.